Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics

Hertz, Barbara; Watabe, Tadashi; Baum, Richard P.

Annals of Nuclear Medicine, 2022, 36, 1007-1009

アクセス数:19件（2026-07-28 02:54 集計）

固定URL: https://hdl.handle.net/11094/105196

閲覧可能ファイル 

ファイル フォーマット 利用条件 サイズ 閲覧回数 利用開始日 説明 information
AnnNuclMed_36_1007 pdf なし 2.46 MB 9 2026.07.06  

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル
Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics
著者
著者名
Hertz, Barbara
NRID
1000090648932 1000090648932
ORCID
0000-0001-8658-2395 0000-0001-8658-2395
researchmap permalink
twosaka2018 twosaka2018
Scopus Author ID
57421862900 57421862900
著者名
Watabe, Tadashi
著者名
Baum, Richard P.
内容
Hertz B., Watabe T., Baum R.P.. Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics. Annals of Nuclear Medicine 36, 1007–1009 (2022); https://doi.org/10.1007/s12149-022-01806-9.
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s12149-022-01806-9
抄録
In 1942, eighty years ago, Dr. Hertz first conducted radioiodine (RAI) diagnosis and therapy for thyroid disorders followed later by the successful treatment of thyroid cancer patients using RAI. In 2022, memorial 80 years later, alpha emitter astatine (²¹¹At), an analogue for iodine, was successfully administered to a patient with refractory thyroid cancer in Japan as a phase-1 clinical trial (first-in-human). Over the past two decades, the use of ⁶⁸Ga labeled peptides for somatostatin receptor (SSTR)-targeted PET imaging followed by beta or alpha emitters labeled SSTR-analogues for peptide receptor radionuclide therapy (PRRT) has demonstrated remarkable success in the management of neuroendocrine neoplasms. In addition, theranostics targeting prostate-specific membrane antigen (PSMA) have dramatically changed the management and treatment of advanced prostate cancer patients. Novel radionuclides and new targets, ligands targeting the tumor microenvironment, optimized peptides and antibodies, combinations of radioligands with immunotherapy, radioprotectors and radiosensitizers as well as new delivery strategies are currently systematically explored. Now the dream of conquering cancer, that Saul Hertz began eight decades ago is coming to fruition.
出版者
Springer
収録物名
Annals of Nuclear Medicine
巻(号)
36
ページ
1007-1009
刊行年月
2022-11-08
言語
英語
ハンドルURL
https://hdl.handle.net/11094/105196
PISSN
09147187
eISSN
18646433
関連情報 (isVersionOf)
DOI (出版社版)
https://doi.org/10.1007/s12149-022-01806-9
アクセス権
open access
出版タイプ
Accepted Manuscript
カテゴリ
学術雑誌論文 Journal Article